MIR155HG
HSPA8-interacting micropeptide miPEP155
Also known as: P155_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for MIR155HG in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
17 residues, UniProt reviewed canonical sequence.
>C0HMA1|MIR155HG
1 MEMALMVAQT RKGKSVVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MIR155HG can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.71
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MIR155HG as an antibody target. Whether an autoantibody or antibody against MIR155HG could matter depends on whether native MIR155HG is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MIR155HG is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MIR155HG as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...